Human Metabolome Technologies, Inc. (TYO:6090)

Japan · Delayed Price · Currency is JPY

606.00

+2.00 (0.33%)

Sep 16, 2026, 3:04 PM JST

Market Cap	3.36B -19.5%
Revenue (ttm)	1.42B -2.3%
Net Income	200.00M -21.9%
EPS	35.64 -18.2%
Shares Out	5.56M
PE Ratio	16.95
Forward PE	n/a
Dividend	18.00 (2.93%)
Ex-Dividend Date	Jun 29, 2026

Volume	1,500
Open	604.00
Previous Close	604.00
Day's Range	604.00 - 610.00
52-Week Range	570.00 - 766.00
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2026

About TYO:6090

Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, prec... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2003

Employees 62

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 6090

Full Company Profile

Financial Performance

In fiscal year 2026, TYO:6090's revenue was 1.42 billion, a decrease of -2.34% compared to the previous year's 1.46 billion. Earnings were 200.00 million, a decrease of -21.88%.

Financial Statements